Lactose acidized glycyrrhetinic chitosan material and preparation method and application thereof

Abstract

The invention relates to a lactose acidized glycyrrhetinic chitosan material and a preparation method and the application thereof. The lactose acidized glycyrrhetinic chitosan material is a glycyrrhetinic acid and lactobionic acid jointly modified chitosan material which is synthesized through N-acylation reaction with chitosan serving as carrier and glycyrrhetinic acid and lactobionic acid serving as ligands. The invention further provides a lactose acidized glycyrrhetinic chitosan / 5-fluorouracil medicine carrying nano particle. The lactose acidized glycyrrhetinic chitosan material and the preparation method and the application thereof have the advantages that the dual-ligand co-modified chitosan material is synthesized for the first time, and the nano particle is prepared for target research; and the lactose acidized glycyrrhetinic chitosan which is prepared into the nano particle has higher liver targeting performance and hepatoma cell receptor mediate initiative targeting performance as compared with GA (glycyrrhetinic acid )-CTS (chitosan) and CTS, distribution in other visceral organs can be evidently reduced, reliability in hepatoma targeting is improved, and the lactose acidized glycyrrhetinic chitosan material can be used as a carrier material which has wide application prospect in clinical hepatoma targeted treatment.

Description

technical field

[0001] The invention relates to the field of polymer drug carriers, in particular to a lactose acidified glycyrrhetinic acid chitosan material and its preparation method and application. Background technique

[0002] At present, domestic and foreign research on liver cancer is mainly focused on the preparation of drug-loaded (or gene) nanoparticles by single-ligand modified polymers. For example, studies on liver-targeting nanoparticles mediated by asialoglycoprotein receptor (ASGP-R) have shown that they have hepatotropism and have certain inhibitory effects on liver cancer. Glycyrrhetinic acid receptor-mediated Active targeting of the liver has the same effect. However, such single-ligand-modified nanoparticles are susceptible to changes in many pathological and physiological conditions during receptor-ligand interactions, resulting in partial failure of receptor-mediated effects and affecting the effect of targeted therapy. For example, for patients with...

Images